Stock MRK MERCK KGAA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra
Other stock markets
 11:35:29 2024-05-17 am EDT 		5-day change 1st Jan Change
167.2 EUR -0.89% Intraday chart for Merck KGaA +7.52% +16.03%
May. 16 MERCK KGAA : DZ Bank gives a Buy rating ZD
May. 16 MERCK KGAA : Gets a Buy rating from Barclays ZD

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 45,804 61,021 98,695 78,651 62,651 72,695 - -
Enterprise Value (EV) 1 58,160 71,683 107,596 86,979 62,651 72,695 77,183 75,079
P/E ratio 34.7 x 30.7 x 32.3 x 23.6 x 22.2 x 24.1 x 20.5 x 18.5 x
Yield 1.23% 1% 0.81% 1.22% - 1.36% 1.45% 1.52%
Capitalization / Revenue 2.84 x 3.48 x 5.01 x 3.54 x 2.98 x 3.42 x 3.24 x 3.07 x
EV / Revenue 2.84 x 3.48 x 5.01 x 3.54 x 2.98 x 3.42 x 3.24 x 3.07 x
EV / EBITDA 10.4 x 11.7 x 16.2 x 11.5 x 10.7 x 12.2 x 11.1 x 10.2 x
EV / FCF 22.4 x 29.6 x 27.8 x 28.8 x - 25.1 x 24 x 21.2 x
FCF Yield 4.46% 3.38% 3.6% 3.47% - 3.99% 4.17% 4.71%
Price to Book 2.56 x 3.59 x 4.63 x 3.03 x - 2.52 x 2.32 x 2.13 x
Nbr of stocks (in thousands) 434,778 434,778 434,778 434,778 434,778 434,778 - -
Reference price 2 105.4 140.4 227.0 180.9 144.1 167.2 167.2 167.2
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,152 17,534 19,687 22,232 20,993 21,249 22,469 23,673
EBITDA 1 4,385 5,201 6,103 6,849 5,879 5,963 6,541 7,109
EBIT 1 2,120 2,985 4,179 4,474 3,609 4,039 4,590 5,101
Operating Margin 13.13% 17.02% 21.23% 20.12% 17.19% 19.01% 20.43% 21.55%
Earnings before Tax (EBT) 1 1,735 2,630 3,924 4,287 3,484 3,799 4,383 4,886
Net income 1 1,320 1,987 3,055 3,326 2,824 2,982 3,476 3,866
Net margin 8.17% 11.33% 15.52% 14.96% 13.45% 14.03% 15.47% 16.33%
EPS 2 3.040 4.570 7.030 7.650 6.490 6.946 8.152 9.057
Free Cash Flow 1 2,043 2,065 3,550 2,728 - 2,898 3,033 3,423
FCF margin 12.65% 11.78% 18.03% 12.27% - 13.64% 13.5% 14.46%
FCF Conversion (EBITDA) 46.6% 39.7% 58.17% 39.83% - 48.6% 46.37% 48.15%
FCF Conversion (Net income) 154.77% 103.9% 116.22% 82.02% - 97.19% 87.26% 88.54%
Dividend per Share 2 1.300 1.400 1.850 2.200 - 2.277 2.425 2.550
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/7/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 8,489 5,213 5,198 5,568 5,806 5,660 5,293 5,302 5,173 5,225 5,120 5,235 5,381 5,529 - -
EBITDA 1 2,256 1,464 1,629 1,782 1,810 1,628 1,587 1,553 1,446 1,293 1,454 1,415 1,520 1,680 - -
EBIT 1 - 1,039 1,173 1,177 1,234 889.6 1,035 969 983 621 931 807.2 1,068 1,129 - -
Operating Margin - 19.93% 22.57% 21.14% 21.26% 15.72% 19.55% 18.28% 19% 11.89% 18.18% 15.42% 19.85% 20.42% - -
Earnings before Tax (EBT) 1 - 991.9 1,139 1,122 1,187 839.1 1,012 894 937 641 899 782.1 1,043 1,097 - -
Net income 1 - 802.1 880.4 867.1 923.2 655 796 704 739 586 694 697 810.6 872.3 - -
Net margin - 15.39% 16.94% 15.57% 15.9% 11.57% 15.04% 13.28% 14.29% 11.22% 13.55% 13.31% 15.07% 15.78% - -
EPS 2 1.720 1.840 2.020 1.990 2.120 1.510 1.830 1.620 1.700 1.340 1.600 1.603 1.875 2.018 - -
Dividend per Share 2 - 1.850 - - - 2.200 - - - - - 0.5500 0.5500 0.5500 0.6000 0.6000
Announcement Date 8/6/20 3/3/22 5/12/22 8/4/22 11/10/22 3/2/23 5/11/23 8/3/23 11/9/23 3/7/24 5/15/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 12,357 10,662 8,902 8,328 - - 4,488 2,384
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) 2.818 x 2.05 x 1.459 x 1.216 x - - 0.6862 x 0.3354 x
Free Cash Flow 1 2,043 2,065 3,550 2,728 - 2,898 3,033 3,423
ROE (net income / shareholders' equity) 13.8% 16.7% 19.8% 18.5% - 13.6% 14% 14.2%
ROA (Net income/ Total Assets) 3.27% 4.64% 8.7% 9.31% - 6.51% 7.36% 7.72%
Assets 1 40,348 42,804 35,111 35,718 - 45,784 47,208 50,066
Book Value Per Share 2 41.10 39.10 49.10 59.60 - 66.40 72.20 78.40
Cash Flow per Share 2 6.580 8.000 10.60 9.800 - 10.20 11.40 12.50
Capex 1 813 1,413 1,066 1,531 - 1,689 1,960 1,978
Capex / Sales 5.03% 8.06% 5.41% 6.89% - 7.95% 8.72% 8.35%
Announcement Date 3/5/20 3/4/21 3/3/22 3/2/23 3/7/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Merck KGaA

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
167.2 EUR
Average target price
182.3 EUR
Spread / Average Target
+9.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+16.03% 79.03B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.23% 8.96B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.76% 5.19B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+51.58% 4.77B
YUHAN CORPORATION Stock Yuhan Corporation
+12.50% 4.26B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-20.70% 2.37B
INDIVIOR PLC Stock Indivior PLC
+12.83% 2.3B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.65% 2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+19.51% 2.17B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Financials Merck KGaA
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW